DB
JSPR icon

Dmitry Balyasny’s Jasper Therapeutics JSPR Stock Holding History

Dmitry Balyasny’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,743
Closed -$277K – 3006
2024
Q3 		$277K Buy
+14,743
New +$294K ﹤0.01% 2474
2024
Q2 		– Sell
-8,417
Closed -$247K – 2847
2024
Q1 		$247K Buy
+8,417
New +$150K ﹤0.01% 2327

Other funds holding JSPR

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Dmitry Balyasny's JSPR Position: Q4 2024 in Review

Dmitry Balyasny sold out of Jasper Therapeutics (JSPR) in Q4 2024, closing a stake of 14,743 shares — an estimated $277K sold.

Dmitry Balyasny first reported a position in JSPR in Q1 2024 and held it in 2 quarters. The position peaked at $277K in Q3 2024. 87 funds tracked by Wall St. Rank hold JSPR as of Q4 2024.

  • Dmitry Balyasny reported no remaining Jasper Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Dmitry Balyasny sold 14,743 Jasper Therapeutics shares in Q4 2024, an estimated $277K.
  • Dmitry Balyasny first reported a position in Jasper Therapeutics in Q1 2024 and held it in 2 quarters.
  • Dmitry Balyasny's Jasper Therapeutics position peaked at $277K in Q3 2024.
  • 87 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2024.

Based on Balyasny Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.